

Anti-HBc IgM

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

cobas®

REF 11820567 160

100 tests

- Indicates analyzers on which the kit can be used

cobas e 601

English

Warning

- Federal law restricts this device to sale and distribution by or on the order of a physician, or to a clinical laboratory; and use is restricted by or on the order of a physician.
- Assay performance characteristics have not been established in patients under the age of 21, pregnant women, or in populations of immunocompromised or immunosuppressed patients.
- This assay has not been FDA licensed for the screening of blood, plasma and tissue donors.

Intended use

The Elecsys Anti-HBc IgM immunoassay is intended for the in vitro qualitative determination of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum or plasma (potassium EDTA, lithium heparin, sodium heparin, sodium citrate) in adult patients with symptoms of hepatitis or who may be at risk for hepatitis B (HBV) infection. The presence of anti-HBc IgM, in conjunction with other laboratory results and clinical information, is indicative of acute or recent hepatitis B virus (HBV) infection. The Elecsys Anti-HBc IgM immunoassay's performance has not been established for the monitoring of HBV disease or therapy. The electrochemiluminescence Immunoassay "ECLIA" is intended for use on the cobas e 601 immunoassay analyzer.

Summary^{1,2,3,4,5,6,7,8,9}

Hepatitis B core antigen (HBcAg) is a non-glycosylated protein (p22) which forms the nucleocapsid (virus core) of the hepatitis B virus. The virus core encloses the HBV-DNA (virus genome) and the DNA-polymerase. In the cytosol of virus-producing hepatocytes the nucleocapsid is enveloped by the hepatitis B surface antigen (HBsAg) to form virions. Free HBcAg or non-enveloped virus cores are not detectable in serum.

IgM antibodies to HBcAg occur in serum during proliferation of active hepatitis B virus and can still be detected weeks to months after viral proliferation has ceased. High anti-HBc IgM concentrations can be found in acute hepatitis B and in attacks during chronic hepatitis B.

Tests for detecting anti-HBc IgM antibodies are used, in conjunction with HBsAg determinations, to identify acute hepatitis B viral infections. An acute attack of hitherto non-diagnosed chronic hepatitis B clinically resembles an acute hepatitis B infection and cannot be distinguished from this with certainty by determining the anti-HBc IgM. Follow-up studies, imaging procedures and liver biopsies are useful in differentiating between these two clinical pictures.

Test principle

μ-Capture test principle. Total duration of assay: 18 minutes.

- 1st incubation: Pretreatment of 10 μL of sample (automatically prediluted 1:400 with Elecsys Diluent Universal) with anti-Fdy reagent to block specific IgG.
- 2nd incubation: Biotinylated monoclonal h-IgM-specific antibodies, HBcAg labeled with a ruthenium complex^a and streptavidin-coated microparticles are added to the pretreated sample. Anti-HBc IgM antibodies present in the sample react with the ruthenium-labeled HBc antigen and the biotinylated anti-h-IgM to form a sandwich complex which becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

- Results are determined automatically by the software by comparing the electrochemiluminescence signal obtained from the reaction product of the sample with the signal of the cutoff value previously obtained by anti-HBc IgM calibration.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Pretreatment anti-HBc IgM (gray cap), 1 bottle, 10 mL: Sample pretreatment reagent: Anti-human-Fdy-antibody (sheep) > 0.05 mg/mL; phosphate buffer 100 mmol/L, pH 7.4; preservative.
- R2 Anti-h-IgM-Ab-biotin; HBcAg-Ru(bpy)₃²⁺ (black cap), 1 bottle, 10 mL: Biotinylated monoclonal anti-h-IgM antibody (mouse) > 600 ng/mL; HBcAg (*E. coli*; rDNA), labeled with ruthenium complex > 200 ng/mL; phosphate buffer 100 mmol/L, pH 7.4; preservative.
- Cal1 Negative calibrator 1 (white cap), 2 bottles of 1.0 mL each: Human serum, preservative.
- Cal2 Positive calibrator 2 (black cap), 2 bottles of 1.0 mL each: Anti-HBc IgM (human) > 100 PEI U/mL^b in human serum; preservative.
- b) Paul-Ehrlich-Institute units

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents. Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

All human material should be considered potentially infectious.

The negative calibrator (Cal1) has been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV. The testing methods applied were FDA-approved or cleared in compliance with the European Directive 98/79/EC, Annex II, List A.

Positive calibrator (Cal2): Materials of human origin were tested for HIV and hepatitis C. The findings were negative. The serum containing anti-HBc IgM was inactivated using β-propiolactone and UV-radiation.

However, as no inactivation or testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.^{10,11}

The reagents may not be used after the stated expiration date.

Avoid foam formation in all reagents and sample types (specimens, calibrators, and controls).

Reagent handling

The reagents in the kit are ready for use and are supplied in bottles compatible with the system.

Unless the entire volume is necessary for calibration on the analyzer, transfer aliquots of the ready-for-use calibrators into empty snap-cap bottles (CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots for later use at 2-8 °C.

Perform **only one** calibration procedure per aliquot.

All information required for correct operation is read in from the respective reagent barcodes.



Anti-HBc IgM

cobas®

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

Storage and stability

Store at 2-8 °C.

Store the Elecsys Anti-HBc IgM reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagent rack pack:

unopened at 2-8 °C	up to the stated expiration date
M, R1, R2 after opening at 2-8 °C	8 weeks
on the analyzer	8 weeks if stored continuously onboard

Stability of the calibrators:

Cal1, Cal2 after opening at 2-8 °C	8 weeks
on the analyzer	use only once

Store the calibrators **upright**! Ensure that no calibration solution is trapped in the opened snap-cap.

Specimen collection and preparation

Serum should be collected using standard sampling tubes or tubes containing separating gel.

Only the specimens listed below were tested and found acceptable.

Lithium heparin, sodium heparin, K₂-EDTA and sodium citrate plasma.

Serum and plasma should be separated from the cells within 2 hours from the time of collection. Test samples as soon as possible after collection.

Store samples at 2-8 °C if not tested immediately.

Serum and plasma samples are stable for 7 days at 2-8 °C, 3 months at -20 °C. The samples may be frozen and thawed up to 6 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer. Do not use samples and controls stabilized with azide.

Centrifuge samples containing precipitates and previously frozen samples before performing the assay.

Ensure the samples, calibrators and controls are at ambient temperature (20-25 °C) before measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzer should be analyzed/measured within 2 hours.

Materials provided

See "Reagents - working solutions" section for reagents.

- 2 x 6 bottle labels

Materials required (but not provided)

- [REF] 11876333160, PreciControl Anti-HBc IgM, 8 x 1.0 mL each of PreciControl Anti-HBc IgM 1 and 2
- [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent
- [REF] 11776576322, CalSet Vials, 2 x 56 empty snap-cap bottles
- General laboratory equipment
- cobas e 601 analyzer

Accessories for cobas e 601 analyzer:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 03004899190, PreClean M, 5 x 600 mL detection cleaning solution
- [REF] 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags
- [REF] 03023150001, Wasteliner, waste bags
- [REF] 03027651001, SysClean Adapter M
- [REF] 11298500160, Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

PreClean M solution is necessary.

Bring the cooled reagents to approx. 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system **automatically** regulates the temperature of the reagents and the opening/closing of the bottles.

Place the calibrators Cal1 and Cal2 in the sample zone of the analyzers.

Only keep open during calibration. All information necessary for calibration is encoded on the barcoded bottle labels and is read in automatically.

After calibration has been performed, discard.

Calibration

Traceability: This method has been standardized against the "HBc-Reference Serum 84 (anti-HBc IgM)" of the Paul-Ehrlich-Institute, Langen (Germany).

Calibration frequency: Calibration must be performed once per reagent lot using Elecsys Anti-HBc IgM Cal1 and Cal2, and fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings with Elecsys PreciControl Anti-HBc IgM reagents outside the defined limits
- more frequently when this is required by pertinent regulations

Range for the electrochemiluminescence signals (counts) for the calibrators:

Negative calibrator (Cal1): 400-3500

Positive calibrator (Cal2): 18000-130000

Quality control

For quality control, use Elecsys PreciControl Anti-HBc IgM.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration. The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits.

Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Note:

For technical reasons re-assigned target values valid for a specific reagent and control lot combination only, must be entered manually. Therefore, always consider the value sheet included in the rackpack or PreciControl kit to make sure that the correct target values are used.

When a new reagent or control lot is used, the analyzer will use the original values encoded in the control barcodes.



Anti-HBc IgM

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

Results

The analyzer automatically calculates the cutoff based on the measurement of Cal1 and Cal2.

The result of a sample is given in the form of a cutoff index (signal sample/cutoff) with a result interpretation of:

- "non-reactive" (COI < 0.9)
- "border"^c (0.9 ≤ COI < 1.1)
- "reactive" (COI ≥ 1.1)

c) border = borderline

Interpretation of results:

Initial Elecsys Anti-HBc IgM assay result			
COI	Result	Interpretation of results	Retest procedure
< 0.9	Non-reactive ^d	No IgM antibodies to HBc were detected	No retest required
0.9 ≤ COI < 1.1	Border	Borderline zone (undetermined)	Retest in duplicate with the Elecsys Anti-HBc IgM assay
≥ 1.1	Reactive	IgM antibodies to HBc detected	Presumptive evidence of IgM antibodies to HBc. Follow CDC recommendations for ancillary testing. No retest required.

d) Please note: A negative anti-HBc IgM result can indicate that the patient is either susceptible to HBV infection due to no past exposure, is chronically infected with HBV, or is immune to HBV infection due to a resolved past infection or vaccination.

Final Elecsys Anti-HBc IgM assay result			
Initial result (COI)	Result after retest (COI)	Final results	Interpretation of results
< 0.9	No retest required	NON-REACTIVE ^e	IgM antibodies to HBc were not detected; does not exclude the possibility of exposure to HBV
0.9 ≤ COI < 1.1	If 2 of the 3 results have a COI < 1.0	NON-REACTIVE	IgM antibodies to HBc were not detected; does not exclude the possibility of exposure to HBV
	If 2 of the 3 results have a COI ≥ 1.0	REACTIVE	Presumptive evidence of IgM antibodies to HBc. Follow CDC recommendations for ancillary testing.
≥ 1.1	No retest required	REACTIVE	Presumptive evidence of IgM antibodies to HBc. Follow CDC recommendations for ancillary testing.

e) Please note: A negative anti-HBc IgM result can indicate that the patient is either susceptible to HBV infection due to no past exposure, is chronically infected with HBV, or is immune to HBV infection due to a resolved past infection or vaccination.

Cutoff determination

The cutoff value was established with in-house studies by measuring a panel of 168 samples. For the Elecsys Anti-HBc IgM immunoassay, the cutoff (cutoff index 1.0) was set to approx. 45 PEI U/mL.

A Receiver Operator Curve (ROC) analysis was used to verify the cutoff. Validation of the cutoff was performed by external clinical studies.

Limitations - interference

Current methods for the detection of IgM antibodies to hepatitis B core (HBc) antigen may not detect all infected individuals. A non-reactive test result does not exclude the possibility of exposure to HBV.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Drug interference studies were performed in vitro, and may not assess the potential interferences that might be seen after the drugs are metabolized in vivo.

A reactive anti-HBc IgM result does not exclude co-infection by another hepatitis virus.

The detection of anti-HBc IgM antibodies indicates either an acute infection with hepatitis B virus or an acute attack in an individual with chronic hepatitis B infection.

cobas[®]

False negative results may occur due to antibody levels below the detection limit of this assay or if the patient's antibodies do not react with the antigen used in this test.

False positive results due to non-specific reactivity cannot be ruled out with the Elecsys Anti-HBc IgM assay.

In rare cases, interference due to extremely high titers of antibodies to immunological components, streptavidin and ruthenium can occur. Results obtained with the Elecsys Anti-HBc IgM immunoassay may not be used interchangeably with values obtained with different manufacturers' assay methods.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Endogenous interferences

To evaluate the effect of elevated levels of hemoglobin, bilirubin, intralipid, biotin and total protein on the Elecsys Anti-HBc IgM assay, the following samples were tested. The results are presented below:

Interferent tested	No interference up to:
Hemoglobin	2 g/dL or 1.2 mmol/L
Bilirubin	25 mg/dL or 428 μmol/L
Lipemia	1000 mg/dL
Biotin	100 ng/mL or 409 nmol/L
Total protein	12 g/dL

Dilution

Use Elecsys Diluent Universal for automatic sample predilution.

Specific performance data

Representative performance data on the analyzer are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined with 1 cobas e 601 analyzer at 1 site using 1 lot of Elecsys reagent to test 4 serum pools and 2 controls in accordance with CLSI (Clinical and Laboratory Standards Institute) guideline EP5-A2. The following results were obtained.

cobas e 601 analyzer						
Sample	N	Repeatability ^f			Intermediate precision ^g	
		Mean COI ^h	SD COI	CV %	SD COI	CV %
HS ⁱ , negative	48	0.069	0.001	1.4	0.001	2.1
HS, high negative	48	0.942	0.025	2.6	0.032	3.4
HS, low positive	48	1.17	0.032	2.7	0.040	3.4
HS, positive	48	2.48	0.077	3.1	0.171	6.9
PCA-HBCIGM1	48	0.071	0.001	1.4	0.001	1.9
PC A-HBCIGM2	48	3.43	0.098	2.8	0.121	3.5

f) Repeatability = within-run precision

g) Intermediate precision = within-laboratory

h) COI = cutoff index

i) HS = human serum

j) PC = PreciControl

Reproducibility study

Precision was further evaluated incorporating between-run, between-day, between-lot, and between-site variation. A reproducibility study was conducted following CLSI EP5-A2 and CLSI EP15-A2 at 3 sites incorporating a 4 member panel consisting of 3 near cutoff human serum pools, 1 moderately reactive human serum pool, and PreciControl Anti-HBc IgM 1 and 2 that were assayed for 5 days, 2 runs per day, 3 replicates per run. The analysis of data was based on guidance from CLSI documents EP5-A2 and EP15-A2. Data from all 3 reagent lots were combined to achieve SD and percent CV for repeatability (within-run), between-run, between-day, between-lot, between-site and reproducibility. The overall imprecision data are summarized in the following table:



Anti-HBc IgM

cobas®

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

Elecsys Anti-HBc IgM reproducibility on the cobas e 601 analyzer

Sample		HS1	HS2	HS3	HS4	PC*1	PC2
N		180	180	180	180	180	180
Mean	COI	0.824	1.05	1.53	1.22	0.092	3.23
Repeatability	SD	0.035	0.052	0.061	0.049	0.002	0.100
	% CV	4.2	4.9	4.0	4.0	2.1	3.1
Between-run	SD	0.029	0.000 ^l	0.000 ^l	0.014	0.000 ^l	0.079
	% CV	3.5	0.0	0.0	1.1	0.0	2.4
Between-day	SD	0.000 ^l	0.018	0.032	0.015	0.001	0.005
	% CV	0.0	1.7	2.1	1.3	1.6	0.2
Between-lot	SD	0.064	0.078	0.100	0.098	0.018	0.273
	% CV	7.8	7.4	6.5	8.0	19.9	8.5
Between-site	SD	0.000 ^l					
	% CV	0.0	0.0	0.0	0.0	0.0	0.0
Reproducibility	SD	0.079	0.095	0.121	0.112	0.018	0.301
	% CV	9.5	9.0	8.0	9.2	20.1	9.3

k) PC = PreciControl Anti-HBc IgM

l) SD of zero due to variance contributed by particular component was below stated significant figure.

Drug interferences





A drug interference study was performed with 18 common therapeutic drugs. Each drug was tested three-fold spiked into a negative, a low positive and a positive sample.

Each drug was found to be non-interfering at the following claimed concentrations:

Compound	Concentration
Acetyl cysteine	150 mg/L
Ampicillin-Na	1000 mg/L
Ascorbic acid	300 mg/L
Ca-Dobesilate	200 mg/L
Cyclosporine	5 mg/L
Cefoxitin	2500 mg/L
Heparin	5000 U
Intralipid	10000 mg/L
Levodopa	20 mg/L
Methyldopa+ 1.5	20 mg/L
Metronidazole	200 mg/L
Phenylbutazone	400 mg/L
Tetracycline	50 mg/L
Acetylsalicylic acid	1000 mg/L
Rifampicin	60 mg/L
Acetaminophen	200 mg/L
Ibuprofen	500 mg/L
Theophylline	100 mg/L


Matrix effects

Studies were conducted to evaluate the suitability of the following 5 types of blood collection tubes: serum/gel separation tubes, lithium-heparin plasma, sodium heparin plasma, K₂-EDTA plasma and sodium citrate plasma. Samples were collected into matched serum and plasma collection tubes and assayed in triplicate. The study was conducted using negative, high-negative, low-positive and positive samples for anti-HBc IgM. The studies support the use of serum/gel separation tubes and the following plasma types: lithium heparin plasma, sodium heparin plasma, K₂-EDTA plasma and sodium citrate plasma. The results are shown below:



Anti-HBc IgM

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)



Analytical specificity

A study was conducted to evaluate the Elecsys Anti-HBc IgM assay for potential cross-reactivity in specimens from individuals with medical conditions unrelated to hepatitis B infection. All specimens in the study were evaluated with the Elecsys Anti-HBc IgM and the reference assay. The results are summarized in the following table:

Reactivity of the Elecsys Anti-HBc IgM assay in individuals with medical conditions unrelated to hepatitis B infection

Category	anti-HBc IgM reference assay				Total samples
	RX ^m		NR ⁿ		
	Elecsys Anti-HBc IgM assay				
	RX	NR	RX	NR	
Autoimmune (AMA, ANA, SLE)	0	0	0	12	12
Cytomegalovirus (anti-CMV)	0	0	0	11	11
Epstein-Barr virus (anti-EBV)	0	0	0	9	9
<i>E. coli</i> infection	0	0	0	9	9
Flu vaccination	0	0	0	10	10
Hepatitis A virus (anti-HAV total)	0	0	0	9	9
HAV vaccination	0	0	0	9	9
HBV vaccination	0	0	0	7	7
Hepatitis C virus (anti-HCV)	0	0	0	11	11
Hepatitis D virus (anti-HDV)	0	0	0	12	12
Hepatitis E virus (anti-HEV)	0	0	0	10	10
Human immunodeficiency virus (anti-HIV-1)	0	0	0	12	12
Herpes Simplex virus (anti-HSV)	0	0	0	12	12
HTLV I/II	0	0	0	12	12
Non-viral liver disease	0	0	0	33	33
Parvovirus B ₁₉ infection	0	0	0	11	11
Pregnancy	0	0	0	11	11
Rheumatoid factor	0	0	0	14	14
Rubella (anti-Rubella)	0	0	0	9	9
Syphilis	0	0	0	10	10
Toxoplasmosis (anti-Toxo)	0	0	0	14	14
Varicella zoster (Anti-VZV)	0	0	0	9	9
Total	0	0	0	256	256

m) RX = reactive
n) NR = non-reactive

Seroconversion sensitivity

Seroconversion sensitivity of the Elecsys Anti-HBc IgM assay has been shown by testing 7 commercially-sourced seroconversion panels in comparison to a reference anti-HBc IgM immunoassay. The comparison of the seroconversion detection between the 2 assays is summarized in the following table:

Panel ID	Reference anti-HBc IgM		Elecsys Anti-HBc IgM		Difference in days to Elecsys Anti-HBc IgM reactivity (Reference - Elecsys)
	NR	RX	NR	RX	
6278	37	41	37	41	0
6281	41	43	41	43	0
9092	82	89	82	89	0
9093	42	49	56	74	25 (2 draws)
PHM933	16	144	16	144	0
PHM934	14	84	14	84	0
PHM935(M2)	66	68	50	68	0

The Elecsys Anti-HBc IgM assay was reactive in the same bleed as the reference assay in 6 of the 7 panels tested. The Elecsys Anti-HBc IgM assay was reactive 2 draws later than the reference assay in 1 panel, wherein both draws yielded near cutoff testing in both assays before conversion.

Summary of clinical performance

A multicenter study was conducted to evaluate the ability of the Elecsys Anti-HBc IgM assay to detect anti-HBc IgM antibodies in specimens from an intended use population. Of the 1581 specimens tested in the Elecsys Anti-HBc IgM clinical study, 1337 specimens were obtained from individuals at risk of HBV infection due to lifestyle, behavior, occupation, disease state or known exposure event; and 244 specimens were obtained from individuals with signs and symptoms of a hepatitis infection. The 1581 specimens were collected from 3 collection sites located in California (49.6%), Florida (19.9%), and Georgia (30.5%). A demographic summary of the overall specimen population by age and ethnic group is provided in the following tables.

Demographic summary of overall specimen population by age

Age group	Overall		Asymptomatic		Symptomatic	
	N	%	N	%	N	%
21 - 30	142	8.98	130	9.72	12	4.92
31 - 40	247	15.9	219	16.5	28	11.5
41 - 50	673	42.6	567	42.4	106	43.4
51 - 60	459	29.0	372	27.8	87	35.7
61 - 70	57	3.61	46	3.44	11	4.51
71 - 80	2	0.13	2	0.15	0	0.00
Unknown	1	0.06	1	0.07	0	0.00
Total	1581	100	1337	100	244	100

Demographic summary of overall specimen population by ethnicity

Ethnicity	Overall		Asymptomatic		Symptomatic	
	N	%	N	%	N	%
African American/Black	1165	73.7	996	74.5	169	69.3
American Indian/Alaska Native	11	0.70	11	0.82	0	0.00
Asian	14	0.89	10	0.75	4	1.64
Caucasian/White	384	24.3	314	23.5	70	28.7
Pacific Islander	2	0.13	2	0.15	0	0.00
Other	4	0.25	4	0.30	0	0.00
Unknown	1	0.06	0	0.00	1	0.41
Total	1581	100	1337	100	244	100

Of the 1581 at risk subjects, 388 (24.5%) were female and 1193 (75.5%) were male. The mean age of the subjects was 45.8 years (age range: 21 - 75 years). Testing of the specimens was performed at 3 clinical testing sites located in St. Louis, MO, Ft. Lauderdale, FL and Boston, MA. To supplement the clinical study, a total of 148 samples from subjects with increased risk for hepatitis due to living in areas endemic for hepatitis or who were potential candidates for acute disease or reactive anti-HBc IgM status were tested with the Elecsys anti-HBc IgM assay on the cobas e 601 analyzer. Results were compared to the reference assay. The reference method value for samples found to be reactive by either method was



Anti-HBc IgM



IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

determined by consensus of results from the reference method and 2 additional FDA approved anti-HBc IgM assays (2 out of 3).

Results by specimen classification

HBV classifications were determined based on the constellation of test results from an FDA-approved HBV marker panel. Using the reference anti-HBc IgM assay, the specimens were assigned an HBV status based on the algorithm provided in the following table:

Serological classification by FDA-approved HBV panel						
	HBsAg	HBeAg	Anti-HBc IgM	anti-HBc	Anti-HBe	Anti-HBs
Acute	(+)	(+)	(-)	(-)	(-)	(-)
Acute	(+)	(-)	(-)	(-)	(-)	(-)
Acute	(+)	(+)	(+)	(+)	(-)	(-)
Acute	(+)	(-)	(+)	(+)	(+)	(-)
Acute	(+)	(-)	(+)	(+)	(-)	(-)
Acute (late)	(+)	(-)	(+)	(+)	(+)	(+) or eq
Chronic	(+) > 6 mo.					
Chronic	(+) > 6 mo.	(-)	(-)	(+)	(+)	(-)
Chronic	(+) > 6 mo.	(+)	(-)	(+)	(-)	(-)
Chronic	(+)	(+)	(-)	(+)	(-)	(-), (+), eq
Chronic	(+)	(-)	(-)	(+)	(+)	(-), (+)
Chronic	(+)	(-)	(-)	(+)	(+)	(+)
Chronic	(+)	(+)	(-)	(+)	(+)	(-)
Chronic	(+)	(+)	(+)	(+)	(+)	(+)
Early recovery	(-)	(-)	(+)	(+)	(+) or (-)	(-)
Early recovery	(-)	(-)	(+)	(+)	(+)	(+)
Early recovery	(-)	(-)	(-)	(+)	(+), eq, (-)	(-)
Recovery	(-), rr uncnf	(-)	(-)	(+)	(+)	(+) or eq
Recovery	(-)	(-)	(-)	(+)	eq	(+)
Recovery	(-)	(-)	(-)	(-)	(+)	(+)
Recovered or immune due to natural infection	(-)	(-)	(-)	(+)	(-)	(+) or eq
HBV vaccine response	(-), rr uncnf	(-)	(-)	(-)	(-)	(+)
HBV vaccination response (?)	(-)	(-)	(-)	(-)	(-)	eq
Not previously infected	(-)	(-)	(-)	(-)	(-)	(-)
Not previously infected	rr uncnf	(-)	(-)	(-)	(-)	(-)
Not interpretable	rr uncnf	(+)	(+)	(+)	(-)	(-)
Not interpretable	(-)	(-)	(-)	nd	(+)	(-)
Not interpretable	(-)	(-)	(-)	(-)	(+) or eq	(-)

Not interpretable	(-)	(-)	(-)	(-)	eq	(+)
Not interpretable	(-)	(+)	(-)	(-)	(-)	(+) or (-)
Not interpretable	qns	(-)	(-)	(-)	(-)	(-)
Not interpretable	rr uncnf	(+)	(-)	(+)	(-)	(-)
Not interpretable	(+)	(-)	(-)	(-)	(-)	(+)

nd = not done or blank
 eq = equivocal or indeterminate or borderline
 rr uncnf = repeatedly reactive HBsAg with (-) confirmatory testing
 qns = incomplete or unconfirmed HBsAg

Results of HBV classification

Asymptomatic at risk population

The following table compares Elecsys Anti-HBc IgM results on the cobas e 601 analyzer with the results obtained with the reference anti-HBc IgM assay for specimens which have been serologically classified in the asymptomatic at risk of HBV infection cohort.

Comparison of Elecsys Anti-HBc IgM assay on the cobas e 601 analyzer to the reference assay results by HBV classification in the asymptomatic at risk cohort

HBV classification	Reference anti-HBc IgM assay results				Total
	+		-		
	Elecsys Anti-HBc IgM test results				
	+	-	+	-	
Acute	4	0	0	3	7
Chronic	0	0	0	34	34
Early recovery	6	0	0	95	101
Recovery	0	0	0	257	257
Recovered	0	0	0	95	95
HBV vaccination	0	0	0	293	293
Not previously infected	0	0	0	537	537
Not interpretable	0	0	0	13	13
Total	10	0	0	1327	1337

The table below summarizes the percent agreement between the Elecsys Anti-HBc IgM assay and the reference assay with clinically classified samples in the asymptomatic at risk cohort. The table also provides the upper and lower 95 % exact confidence bounds.



Anti-HBc IgM

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

Positive and negative percent agreement in the asymptomatic at risk population

HBV classification	Positive percent agreement (n/N)	95 % Exact confidence interval	Negative percent agreement (n/N)	95 % Exact confidence interval
Acute	100 (4/4)	39.8 - 100	100 (3/3)	29.2 - 100
Chronic	N/A	N/A	100 (34/34)	89.7 - 100
Early recovery	100 (6/6)	54.1 - 100	100 (95/95)	96.2 - 100
Recovery	N/A	N/A	100 (257/257)	98.6 - 100
Recovered	N/A	N/A	100 (95/95)	96.2 - 100
HBV vaccination	N/A	N/A	100 (293/293)	98.8 - 100
Not previously infected	N/A	N/A	100 (537/537)	99.3 - 100
Not interpretable	N/A	N/A	100 (13/13)	75.3 - 100
Total	100 (10/10)	69.2 - 100	100 (1327/1327)	99.7 - 100

The positive percent agreement between the Elecsys Anti-HBc IgM assay results and the HBV infected status for the asymptomatic at risk for HBV infection population (n = 1335) was 100 % (10/10) with a 95 % confidence interval of 69.2-100 %. The negative percent agreement between the Elecsys Anti-HBc IgM assay results with the not HBV infected status was 100 % (1327/1327) with a 95 % confidence interval of 99.7-100 %.

Symptomatic at risk population

The following table compares Elecsys Anti-HBc IgM results on the cobas e 601 analyzer with the results obtained with the reference anti-HBc IgM assay for specimens which have been serologically classified in the symptomatic at risk for HBV infection cohort.

Comparison of Elecsys Anti-HBc IgM assay on the cobas e 601 analyzer to the reference assay results by HBV classification in the symptomatic at risk cohort

HBV classification	Reference anti-HBc IgM assay results				Total
	+		-		
	Elecsys Anti-HBc IgM test results				
	+	-	+	-	
Acute	1	0	0	1	2
Chronic	0	0	0	11	11
Early recovery	2	0	0	26	28
Recovery	0	0	1	33	34
Recovered	0	0	0	25	25
HBV vaccination	0	0	0	45	45
Not previously infected	0	0	0	93	93
Not interpretable	1	0	0	5	6
Total	4	0	1	239	244

The table below summarizes the percent agreement between the Elecsys Anti-HBc IgM assay on the cobas e 601 analyzer and the reference assay with clinically classified samples in the symptomatic at risk cohort. The table also provides the upper and lower 95 % exact confidence bounds.

cobas®

Positive and negative percent agreement in the symptomatic at risk population

HBV classification	Positive percent agreement (n/N)	95 % Exact confidence interval	Negative percent agreement (n/N)	95 % Exact confidence interval
Acute	100 (1/1)	2.50 - 100	100 (1/1)	2.50 - 100
Chronic	N/A	N/A	100 (11/11)	71.5 - 100
Early recovery	100 (2/2)	15.8 - 100	100 (26/26)	86.8 - 100
Recovery	N/A	N/A	97.1 (33/34)	84.7 - 99.9
Recovered	N/A	N/A	100 (25/25)	86.3 - 100
HBV vaccination	N/A	N/A	100 (45/45)	92.1 - 100
Not previously infected	N/A	N/A	100 (93/93)	96.1 - 100
Not interpretable	100 (1/1)	2.50 - 100	100 (5/5)	47.8 - 100
Total	100 (4/4)	39.8 - 100	99.6 (239/240)	97.7 - 100

The positive percent agreement between the Elecsys Anti-HBc IgM assay results and the HBV infected status for the symptomatic at risk population (n = 244) was 100 % (4/4) with a 95 % confidence interval of 39.8-100 %. The negative percent agreement between the Elecsys Anti-HBc IgM assay results with the not HBV infected status was 99.6 % (239/240) with a 95 % confidence interval of 97.7-100 %.

Endemic/acute/reactive population

The following table compares Elecsys Anti-HBc IgM results on the cobas e 601 analyzer with the results obtained with the reference anti-HBc IgM assay for specimens from subjects with increased risk for hepatitis due to living in areas endemic for hepatitis or who were potential candidates for acute disease or reactive anti-HBc IgM status.

Comparison of Elecsys Anti-HBc IgM assay on the cobas e 601 analyzer to the reference assay results by HBV classification in the endemic/acute/reactive cohort

HBV classification	Reference anti-HBc IgM assay results				Total
	+		-		
	Elecsys Anti-HBc IgM test results				
	+	-	+	-	
Acute	29	3	0	13	45
Chronic	1	0	1	94	96
Early recovery	4	0	0	0	4
HBV vaccination	0	0	0	1	1
Not previously infected	0	0	0	2	2
Total	34	3	1	110	148



Anti-HBc IgM

cobas®

IgM antibodies to hepatitis B core antigen (anti-HBc IgM)

HBV classification	Positive percent agreement (n/N)	95 % Exact confidence interval	Negative percent agreement (n/N)	95 % Exact confidence interval
Acute	90.6 (29/32)	75.0 - 98.0	100 (13/13)	75.3 - 100
Chronic	100 (1/1)	2.50 - 100	99.0 (94/95)	94.3 - 100
Early recovery	100 (4/4)	39.8 - 100	N/A	N/A
HBV vaccination	N/A	N/A	100 (1/1)	2.50 - 100
Not previously infected	N/A	N/A	100 (2/2)	15.8 - 100
Total	91.9 (34/37)	78.1 - 98.3	99.1 (110/111)	95.1 - 100

COBAS, COBAS E, ELECSYS and MODULAR are trademarks of Roche. Other brand or product names are trademarks of their respective holders. INTRALIPID is a trademark of Fresenius Kabi AB. Significant additions or changes are indicated by a change bar in the margin. Changes to reagent barcode test parameters which have already been read in should be edited manually. © 2011, Roche Diagnostics

Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336



The positive percent agreement between the Elecsys Anti-HBc IgM assay results and the HBV infected status for the endemic/acute/reactive population (n = 148) was 91.9 % (34/37) with a 95 % confidence interval of 78.1-98.3 %. The negative percent agreement between the Elecsys Anti-HBc IgM assay results with the not HBV infected status was 99.1 % (110/111) with a 95 % confidence interval of 95.1-100 %.

References

- Gudat F, et al. Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B. *Laboratory investigations* 1975;32(1):1-9.
- Gerlich WH, Robinson WS. Hepatitis B virus contains protein attached to the 5' terminus of its complete DNA strand. *Cell* 1980;21:801-809.
- Gerlich WH, Goldmann U, Müller R, et al. Specificity and localization of the hepatitis B virus-associated protein kinase. *Journal of Virology* 1982;42(3):761-766.
- Roosinck MJ, Siddiqui A. In vivo phosphorylation and protein analysis of hepatitis B virus core antigen. *J Virol* 1987;61:955-961.
- Gallina A, et al. A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids. *J Virol* 1989;63(11):4645-4652.
- Zhou S, Stranding DN. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. *Proc Natl Acad Sci USA* 1992;89:10046-10050.
- Birnbaum BS, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. *J Virol* 1990;64(7):3025-3330.
- Hollinger FB. Hepatitis B virus. In Fields BN, Knipe DM (eds) *Virology* 2nd ed., New York, Raven Press 1990:2171-2236.
- Hoofnagle Bisceleglie MD. Serologic diagnosis of acute and chronic viral hepatitis. *Seminars in Liver Disease* 1991;11(2):73-83.
- Occupational Safety and Health Standards: bloodborne pathogens. (29 CFR Part 1910.1030). *Fed. Register*.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information, and Method Sheets of all necessary components.

Limited License

The Elecsys Anti-HBc IgM assay shall not be used by blood banks, donor centers, or other institutions which exclusively or predominantly use the test for the safety or screening of blood and blood products.

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

